What is INTS's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.01B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for INTS?

P/E (TTM) is n/a and 52-week range is $3.21 to $43.50 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s INTS figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for INTS?

The company profile lists net income (TTM) near $-13M, EPS (TTM) near $-4.93 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Intensity Therapeutics Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Shelton, Connecticut, US, 2.7M shares outstanding, ISIN US45828J2024 when available from company profile and filing metadata.

Intensity Therapeutics Inc

$INTS

Health Care · Biotechnology

IR Run Scenarios

$3.63

-1.36%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Intensity Therapeutics, Inc. operates as biotechnology company, which develops novel immune-based therapeutic products for cancer treatment. The company is headquartered in Shelton, Connecticut and currently employs 5 full-time employees. The company went IPO on 2023-06-30. The company is engaged in developing treatments that address both the regional and systemic nature of a patient’s cancer. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its lead product candidate, INT230-6, comprises three components: cisplatin, a proven anti-cancer cytotoxic agent, vinblastine sulfate, also a proven anti-cancer cytotoxic agent, and an amphiphilic molecule (SHAO) which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection. Its pipeline consists of INVINCIBLE-3 Study, a Phase 3 open-label, randomized study testing the superiority INT230-6 used as monotherapy compared to the standard of care drugs in 2nd and 3rd line treatment for certain soft tissue sarcoma subtypes, a Phase 2 clinical study in metastatic triple negative breast cancer.

Employees

Website

www.intensitytherapeutics.com

IPO

2023-06-30

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)